Exp Cell Res. 2004 Jan 1 Lützen A1, Bisgaard HC, Rasmussen LJ. Abstract We have evaluated cell survival, apoptosis, and cell cycle responses in a panel of DNA mismatch repair (MMR)-deficient colon and prostate cancer cell lines after alkylation and UV-C damage. We show that although these MMR-deficient cells tolerate alkylation damage, they are asRead more
Blog
Clin Exp Allergy. 2003 Dec Buchvald F, Eiberg H, Bisgaard H. Abstract BACKGROUND: Nitric oxide in exhaled air is regarded as an inflammation marker, and may be used to monitor the anti-inflammatory control from inhaled corticosteroids (ICSs). However, this response to ICSs exhibits a heterogeneous pattern. OBJECTIVE: The study aimed to describe the independent variablesRead more
Pediatr Pulmonol. 2003 Nov Bisgaard H. Abstract The purpose of this analysis was to examine the effect of long-acting beta(2)-adrenoceptor agonists (LABAs) on the asthma exacerbation rate in pediatric patients. Randomized controlled trials (RCT) that included the use of LABAs to treat symptoms of pediatric asthma in children on inhaled corticosteroids, that reported asthma exacerbationRead more
BMJ. 2003 Oct 18 Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, Holgate ST, Picado C, Menten J, Dass SB, Leff JA, Polos PG. Abstract OBJECTIVES: To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasoneRead more
Ann Allergy Asthma Immunol. 2003 Sep Buchvald F, Bisgaard H. Abstract BACKGROUND: Inhaled, long-acting beta2-agonists or antileukotrienes are alternatives as add-on therapy for asthmatic children taking regular inhaled steroids. Any complementary effects would be relevant to the choice between these alternatives. Exhaled nitric oxide (FeNO) may reflect these effects. OBJECTIVE: To compare the control ofRead more
J Allergy Clin Immunol. 2003 Apr Meyer KA, Arduino JM, Santanello NC, Knorr BA, Bisgaard H. Abstract BACKGROUND: Determining who responds to asthma therapies, particularly leukotriene modifiers, continues to be explored. OBJECTIVE: We sought to identify patient characteristics predictive of response to montelukast. METHODS: We used data from 2 clinical trials in which children withRead more
Am J Respir Crit Care Med. 2003 Feb 1 Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. Abstract Infants often develop reactive airway disease after respiratory syncytial virus (RSV) bronchiolitis. Cysteinyl-leukotrienes (cys-LT) are released during RSV infection and may contribute to the inflammation. We hypothesized that a cys-LT receptor antagonist would ameliorate reactiveRead more
J Allergy Clin Immunol. 2003 Jan Sampson AP, Pizzichini E, Bisgaard H. Abstract The understanding that asthma pathophysiology includes an inflammatory component has spurred the more aggressive use of anti-inflammatory therapies and created a need for effective tools to measure inflammation. Biomarkers of airway inflammation proposed are obtained by methods that are direct but highlyRead more
Carcinogenesis. 2002 Nov Herrmann S, Seidelin M, Bisgaard HC, Vang O. Abstract Indole-3-carbinol (I3C) is a naturally occurring substance that shows anti-carcinogenic properties in animal models. Besides its clear anti-carcinogenic effects, some studies indicate that I3C may sometimes act as a tumor promoter. Indolo[3,2-b]carbazole (ICZ), which is formed in the acidic environment of the stomachRead more
Br J Clin Pharmacol. 2002 Nov Lipworth BJ, Lee DK, Anhøj J, Bisgaard H. Abstract AIMS: To study the effects of electrostatics in a plastic spacer on the lung deposition of salbutamol in asthmatic children. METHODS: Twenty-five children (5-12 years) with mild asthma were given salbutamol hydrofluoroalkane pressurized metered dose inhaler 400 micro g viaRead more
